News

← News

Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand

MONMOUTH JUNCTION, N.J., June 29, 2015; -

Tris Pharma, Inc. ("Tris") today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare.

Under the terms of the agreement, Pfizer Consumer Healthcare will commercialize Tris’ extended release dextromethorphan cough syrup under the Robitussin® Brand. In exchange for providing Pfizer Consumer Healthcare U.S. branded rights to its protected intellectual property for an extended release dextromethorphan formulation, Tris will receive an upfront payment, milestone payments and sales-based royalties. Tris will be responsible for manufacturing and regulatory activities while Pfizer Consumer Healthcare will manage sales, marketing, and distribution.

Pfizer Consumer Healthcare plans to launch extended-release Robitussin in July, prior to the 2015-2016 cough/cold season.

Dextromethorphan is indicated for the treatment of cough due to minor throat and bronchial irritation. According to the National Institute of Health (NIH), each year there are millions of cough/cold suffers and for many of these patients, self-medicating with long-acting dextromethorphan will be the preferred option.

Ketan Mehta, CEO of Tris commented, “The U.S. cough and cold market has been ripe for innovation and when you consider that market research shows most patients prefer long-lasting relief in the form of a liquid, rather than a solid pill, our technology is well positioned to address this market. We are delighted to partner with Pfizer Consumer Healthcare and have our product marketed under the Robitussin® brand, the #1 pharmacist recommended for cough, cold and flu combinations.”

About Tris Pharma:

Tris Pharma is a specialty pharmaceutical company focused on drug delivery technologies based products including difficult-to-formulate or complex generic products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey. 

For more information visit http://www.trispharma.com